Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS)
Teva Pharmaceutical Industries Ltd., 4 Dec 2014
Accessed on 9 Dec 2014 from http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1995004.
